ArticleArthritis & rheumatology (Hoboken, N.J.)2019
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Non-Cardiovascular-Related Deaths.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Impact of gout on cardiovascular disease mortality: a meta-analysis.Zeitschrift fur Rheumatologie · 2024Pooled it
- A Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia.Clinical pharmacology in drug development · 2026Article
- Accuracy and readability of LLM-generated responses for gout management: a benchmark study based on ACR guidelines.Clinical rheumatology · 2026Article
- Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.Nature reviews. Rheumatology · 2025Review
- Hyperuricemia, gout and the associated comorbidities in China: findings from a prospective study of 0.5 million adults.The Lancet regional health. Western Pacific · 2025Article
- Exploring Therapeutic Potential of Bi-Qi Capsules in Treatment of Gout by Discovering Crucial Drug Targets.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effect of gout on 30-day survival in ICU patients: retrospective analysis of a large cohort of critically ill patients.BMC rheumatology · 2025Article
- Efficacy and safety of Jinhuang ointment in treating acute gouty arthritis: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Establishment and evaluation of a model for clinical feature selection and prediction in gout patients with cardiovascular diseases: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- Sex Differences in Clinical Features in Gout: A Nationwide Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Association of serum 25-hydroxyvitamin D concentrations with all-cause and cause-specific mortality among individuals with gout and hyperuricemia.Nutrition journal · 2024Article
- Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors.Arthritis care & research · 2024Article
- Article
- A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.Scientific reports · 2023Article
- Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.JAMA network open · 2023Article
- Risk of Major Adverse Cardiovascular Event Following Incident Hospitalization for Acute Gout: A Western Australian Population-Level Linked Data Study.ACR open rheumatology · 2023Article
- Cause-Specific Mortality in Patients With Gout in the US Veterans Health Administration: A Matched Cohort Study.Arthritis care & research · 2023Article
- Presence of tophi and carotid plaque were risk factors of MACE in subclinical artherosclerosis patients with gout: a longitudinal cohort study.Frontiers in immunology · 2023Article
- Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis.International journal of molecular sciences · 2022Review
- Professionals' perspectives on existing practice and conditions for nurse-led gout care based on treatment recommendations: a qualitative study in primary healthcare.BMC primary care · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
objectiveTo examine cause-specific mortality beyond cardiovascular diseases (CVDs) in patients with gout compared to the general population.
methodsWe included all residents of Skåne (Sweden) age ≥18 years in the year 2002. Using the Skåne Healthcare Register, we identified subjects with a new diagnosis of gout (2003-2013) and matched each person with gout with 10 comparators free of gout, by age and sex. We used information on the underlying cause of death from the Swedish Cause of Death Register (through December 31, 2014) to estimate hazard ratios (HRs, with 95% confidence intervals [95% CIs]) of mortality for specific causes of death in a multi-state Cox model, with adjustment for potential confounders.
resultsAmong 832,258 persons, 19,497 had a new diagnosis of gout (32% women) and were matched with 194,947 comparators. Subjects with gout had higher prevalence of chronic kidney disease, metabolic disease, and CVD. Gout was associated with 17% increased hazard of all-cause mortality overall (HR 1.17 [95% CI 1.14-1.21]), 23% in women (HR 1.23 [95% CI 1.17-1.30]), and 15% in men (HR 1.15 [95% CI 1.10-1.19]). In terms of cause-specific mortality, the strongest associations were seen in the relationship of gout to the risk of death due to renal disease (HR 1.78 [95% CI 1.34-2.35]), diseases of the digestive system (HR 1.56 [95% 1.34-1.83]), CVD (HR 1.27 [95% CI 1.22-1.33]), infections (HR 1.20 [95% CI 1.06-1.35]), and dementia (HR 0.83 [95% CI 0.72-0.97]).
conclusionSeveral non-CV causes of mortality are increased in persons with gout, emphasizing the need for improved management of comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.